[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fibroid-uterus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fibroid-uterus":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,55,85,111,139,169,195,224,251],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":35,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100644230","phase-4-cyclobenzaprine-for-postoperative-pain-in-minimally-invasive-hysterectomy-100644230",false,"NCT07664956","Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy","Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age \\>18yo\n* Female\n* English speaking\n* Undergoing (robotic assisted or classic) total laparoscopic hysterectomy ± unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy\n* If other procedures such as lysis of adhesions, excision of endometriosis, or ureterolysis are indicated based on intraoperative evaluation, those patients may still be included\n* Surgery took place at ChristianaCare Hospitals\n* No allergies or contraindications to standard of care post operative pain medications (acetaminophen, NSAIDs, narcotics) or cyclobenzaprine\n\nExclusion Criteria:\n\n* Age \\\u003C18yo\n* Male\n* Pregnant, breastfeeding\n* Non-English speaking\n* Primary procedures other than laparoscopic hysterectomy\n* Laparoscopic myomectomy\n* Laparoscopic resection of endometriosis\n* Laparoscopic unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy ± unilateral or bilateral cystectomy without hysterectomy\n* Hysteroscopic procedures\n* Bartholin gland marsupialization\n* Operations that are scheduled as or converted to the open approach\n* Procedures with planned or unplanned bladder or bowel surgery\n* Allergies or contraindications to standard post operative pain control medications (acetaminophen, NSAIDs, narcotics), such as kidney or liver damage\u002Ffailure, bariatric surgery, history of gastric ulcer, etc.\n* Chronic pain issues, whether self-diagnosed or by a physician, currently undergoing management\n* Currently undergoing medication assisted treatment for opioid use disorder\n* Currently using opioids consistently\n* Allergies or contraindications to cyclobenzaprine:\n* Absolute: use of MAO inhibitors within 14 days, recent heart attack, congestive heart failure, heart block or other conduction abnormalities, cardiac arrhythmias, hyperthyroidism, history of serotonin syndrome\n* Allergies or contraindications to inactive ingredients in Flexeril, such as lactose\n* Patient's receiving gabapentin at baseline or postoperatively, due to potential sedating effects, or other sedating drugs such as scheduled benzodiazepines and barbiturates","FEMALE","18 Years",{"count":19,"type":20},36,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","Typical postoperative pain control after minimally invasive hysterectomy includes ibuprofen, acetaminophen, and a short course of narcotics. The purpose of this study is to see if adding cyclobenzaprine to this regime improves pain control and lessens narcotic use.",[26,27,28,29,30,31,32,33,34],"Minimally Invasive Surgical Procedures","Abnormal Uterine Bleeding, Unspecified","Adenomyosis of Uterus","Fibroid Uterus","Chronic Pelvic Pain","Endometriosis","Menorrhagia","Endometritis","Adnexal Diseases",[36,37,38,39,40,41],"cyclobenzaprine","flexeril","hysterectomy","minimally invasive hysterectomy","pain control","multimodal pain control","NOT_YET_RECRUITING","2026-06-18",{"date":45,"type":46},"2026-06-24","ACTUAL",{"date":48,"type":20},"2026-07-01",{"date":50,"type":20},"2026-12-01",{"name":52,"class":53},"Christiana Care Health Services","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":16,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":21,"phases":68,"briefSummary":69,"conditions":70,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100527120","phase-4-prescription-of-letrozole-for-uterine-myoma-100527120","NCT06143631","Prescription of Letrozole for Uterine Myoma","Letrozole for Treatment of Uterine Fibroids: A Randomized, Placebo-Controlled Trial","PLUM","Inclusion Criteria:\n\n* At least 21 and less than 54 years of age (to focus on an adult, premenopausal population)\n* Female sex, based on sex identified on their birth certificate (no other gender requirements)\n* Have uterine leiomyomata that have been visualized on pelvic imaging (i.e., ultrasound or MRI) in the last 24 months\n* Report symptoms associated with leiomyomata such as heavy uterine bleeding, pelvic pressure or discomfort, urinary or bowel abnormalities, or dyspareunia for the past 3 months\n* Have at least moderate leiomyomata symptom burden, with UFS-QOL SSS score of 30 or higher at baseline\n* Has had a menstrual period in the past 3 months (90 days)\n* Agree to use a non-hormonal or barrier method of contraception with any sexual activity with a non-sterile male partner during the study period (i.e., use of copper IUD is consistent with eligibility)\n\nExclusion Criteria:\n\n* Screening pelvic imaging indicating any leiomyomata ≥10 cm in maximum diameter, or uterine size ≥16 cm in length (equivalent to 16 weeks gestation)-note that candidates who exclusively have prior clinical pelvic imaging 12-24 months ago will be excluded if imaging includes leiomyomata ≥9 cm in maximum diameter, or uterine size ≥15 cm in length, presuming leiomyoma growth of ≥1 cm per year\n* Screening pelvic imaging indicating only one, sole leiomyoma \\\u003C2 cm in maximum diameter\n* Any submucosal leiomyoma that is \\>50% within uterine cavity (FIGO Type 0 or Type 1 leiomyomata)\n* Visit to the emergency room or hospitalization for leiomyoma symptoms in the last 12 weeks\n* Leiomyomata treated by surgery, radiologic procedure in the last 12 weeks; or plans to undergo any of the above in the next 24 weeks\n* Leiomyomata treated by GRNH agonist or antagonist in the last 12 weeks (if injected) or in the last 4 weeks (if oral); or plans to use the above in the next 24 weeks\n* Currently pregnant or lactating, pregnant or lactating in the past 12 weeks, or planning to become pregnant in the next 24 weeks\n* Screening serum hemoglobin \\\u003C8 g\u002FdL, or history of blood transfusion in the last 12 weeks (indicating severe anemia)\n* Screening cholesterol lipid panel testing showing LDL cholesterol level ≥ 190 mg\u002FdL (due to rare side effects over long-term use of aromatase inhibitors in postmenopausal women)\n* Screening serum estradiol level \\\u003C30 pg\u002FmL (consistent with postmenopausal status)\n* For women aged 45 years or older only: irregular menstrual cycles (menstrual cycles \\\u003C21 days or \\>38 days between periods), prolonged menstrual bleeding (bleeding \\>14 days), or bleeding in between menstrual periods, unless already evaluated by a clinician to discuss endometrial biopsy (uterine biopsy) to rule out endometrial hyperplasia.\n* History of osteoporosis (based on self-reported DEXA indicating bone mineral density Z-score \\\u003C -2.0 at spine, total hip, or femoral neck; a prior fracture judged to be a fragility fracture; or self-reported use of bisphosphonates, calcitonin, calcitriol, ipriflavone, teriparatide, or denosumab for bone density loss)\n* History of severe liver disease (Child Pugh Class C cirrhosis), posing safety risks for use of letrozole\n* Current or prior history of breast cancer (given potential need to take letrozole for breast cancer treatment or secondary prevention)\n* Screening pelvic imaging indicating an Ovarian-Adnexal Reporting and Data System (O-RADS) category 3, 4, or 5 ovarian or adnexal lesion\n* Screening pelvic imaging concerning for other current cancer of the gynecologic, genitourinary or gastrointestinal system\n* Prior hypersensitivity or significant adverse reaction to letrozole or any aromatase inhibitor, or to an ingredient in the placebo capsule\n* Use of letrozole, other aromatase inhibitor, or selective estrogen receptor modulator (SERM) medications in the past 4 weeks, or existing plans to initiate one of these in the next 24 weeks\n* Use of oral, vaginal, or topical exogenous estrogen, progestin, or androgen therapy in the past 4 weeks; or injectable forms of the above in the past 12 weeks; or plans to initiate any of the above in the next 24 weeks\n* Use of medications with potential unsafe interactions with letrozole in the past 4 weeks (methadone, levomethadone, nintedanib, thalidomide), or plans to initiate these in the next 24 weeks\n* Any condition that, in the opinion of the investigators, would interfere with ability to complete study procedures, including acute or uncontrolled mental health condition, substance abuse, or inability to complete procedures in English (or Spanish, for sites that offer study assessments in Spanish)",true,"21 Years","53 Years",{"count":67,"type":20},140,[23],"The PLUM Study is a randomized, double-blinded, 2-arm, parallel-group, placebo-controlled trial is designed to compare the efficacy of letrozole versus placebo on leiomyoma-related symptoms and quality of life as well as leiomyoma and uterine size.",[71,72,73,29],"Leiomyoma, Uterine","Leiomyoma","Fibroid","RECRUITING","2026-06-09",{"date":77,"type":46},"2026-06-10",{"date":79,"type":46},"2024-07-24",{"date":81,"type":20},"2027-12-13",{"name":83,"class":53},"University of California, San Francisco",5,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":94,"briefSummary":96,"conditions":97,"keywords":98,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100557315","phase-2-the-effects-of-one-time-intraoperative-methadone-during-laparoscopic-hysterectomy-in-reducing-opioid-prescription-100557315","NCT06536517","The Effects of One-time Intraoperative Methadone During Laparoscopic Hysterectomy in Reducing Opioid Prescription.","A Randomized Controlled Trial to Study the Effects of One-time Intra-operative Dosing of Methadone During Laparoscopic or Robotic Hysterectomy in Reducing Opioid Prescription.","Inclusion Criteria:\n\n* Individuals with a uterus\n* Age 18 years old and above\n* Undergoing minimally invasive (laparoscopic or robotic) hysterectomy with ovarian preservation\n* Benign indications for hysterectomy\n* Agreeing to participate\n\nExclusion Criteria:\n\n* Chronic pain syndromes patients including fibromyalgia\n* Patients currently on long-term (i.e. for more than three months) opioid use\n* Patients currently on agonist-antagonist medications (e.g. buprenorphine)\n* Patients taking a selective serotonin reuptake inhibitor or monoamine oxidase inhibitor\n* Conversion to laparotomy\n* Allergy or other contraindication to the prescribed medications such as methadone, fentanyl, acetaminophen or oxycodone\n* Severe Obstructive Sleep Apnea (OSA)\n* Pregnant\u002Fbreastfeeding patients",{"count":93,"type":20},100,[95],"PHASE2","Currently, there is a nationwide epidemic of opioid abuse and overdose deaths. One source of excess opioids is overprescribing in the postoperative period. This study aims to find the optimal pain medication plan during and after laparoscopic hysterectomy to eliminate long-term opioid use.\n\nGiven the increasing opioid abuse and over-prescription post-operatively, an effort should be made to determine whether one time dosing of Methadone, a longer opioid analgesics, intra-operatively is an adequate potential in treating postoperative pain after hysterectomy surgeries. The investigators hypothesize that this could minimize the need for additional post-operative and outpatient opioid prescriptions and decrease the adverse effects that are associated with the consumption, including new opioid abuse.\n\nIntervention group will receive methadone intraoperatively while the other group would receive short-acting opioids (standard).",[29],[38,99,100],"methadone","opioids","2026-01-09",{"date":103,"type":46},"2026-01-12",{"date":105,"type":46},"2025-03-07",{"date":107,"type":20},"2026-12",{"name":109,"class":53},"Johns Hopkins University",2,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":21,"phases":122,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":54},"100577738","a-randomized-study-comparing-subtotal-vs-total-hysterectomy-long-term-outcomes-100577738","NCT06802198","A Randomized Study Comparing Subtotal vs Total Hysterectomy Long Term Outcomes","Comparison of Long-Term Outcomes Following Laparoscopic Total Vs Supracervical Hysterectomy, a Randomized Clinical Trial","STORY","Inclusion Criteria:\n\n* Age\\>18 years\n* Signed informed consent\n\nExclusion Criteria:\n\n* Uterine or adnexal pathology suspect for malignancy\n* Abnormal or unknown PAP test\n* Patients with invasive neoplasia in the previous 5 years (excluding non-melanoma skin tumors, breast cancer T1 N0 M0 Grade 1 or 2 without signs of recurrence or activity).\n* Previous radical pelvic surgery or radiotherapy;\n* Age \\> 80 years\n* Pregnant patients\n* Desire for further pregnancies\n* Contraindications to general anaesthesia or to the Trendelenburg position\n* Refusal to sign informed consent","80 Years",{"count":121,"type":20},500,[123],"NA","The goal of this randomized clinical trial is to assess the outcomes of total laparoscopic hysterectomy vs subtotal laparoscopic hysterectomy + mini-laparotomy for uterine extraction for benign gynecological conditions in terms of change in quality of life at 36 months after surgery and patient's impression of improvement. The secondary objectives of the study are to assess any differences in terms of peri and postoperative outcomes (postoperative pain, blood loss, hospital stay, intraoperative or short and long-term postoperative complications, long term urinary, bowel and pelvic floor symptoms, prevalence of vaginal cuff dehiscence).\n\nParticipants will fill the following questionnaires pre-operatively and at the follow up:\n\n* Short Form 36 (SF36),\n* Euro Quality of life 5D-3L (EQ 5D-3L)\n* Female Sexual Function Index (FSFI)\n* Patient Global Impression of Improvement (PGI-I) only during the follow-up period.",[29,126,127,128,31,129],"Metrorrhagia","Adenomyosis","Benign Gynecologic Neoplasm","Abnormal Uterine Bleeding","2025-09-04",{"date":132,"type":46},"2025-09-05",{"date":134,"type":20},"2025-10-01",{"date":136,"type":20},"2030-02-01",{"name":138,"class":53},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":148,"phases":4,"briefSummary":149,"conditions":150,"keywords":153,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":54},"100604218","comparison-of-operative-hysteroscopy-performed-in-the-operating-room-versus-outpatient-settings-100604218","NCT07146659","Comparison of Operative Hysteroscopy Performed in the Operating Room Versus Outpatient Settings","Comparison of Operative Hysteroscopy Performed in the Operating Room Versus Outpatient Settings : A Prospective Observational Study","Inclusion Criteria:\n\n* Women aged ≥ 18 years\n\n  -⁃ Undergoing operative hysteroscopy for intrauterine pathology\n* Able to provid e informed non-opposition\n* French-speaking\n\nExclusion Criteria:\n\n* Patients with contraindications to hysteroscopy\n* Pregnancy\n* Inability to complete follow-up",{"count":147,"type":20},400,"OBSERVATIONAL","This is an observational prospective monocentric study which aims to compare operative hysteroscopies performed in the operating room under general or loco-regional anesthesia and those performed outside the operating room (outpatient operative hysteroscopy). The primary outcome is the success rate of the procedure. Secondary outcomes include postoperative pain, patient satisfaction, complications, and time to return to work.",[29,151,152],"Polyp Uterus","Retained Products of Conception",[154,155,156,157,158,159],"Hysteroscopy","Operative hysteroscopy","Outpatient ambulatory","Patient satisfaction","Outpatient hysteroscopy","Complications","2025-08-21",{"date":162,"type":46},"2025-08-28",{"date":164,"type":46},"2025-07-01",{"date":166,"type":20},"2027-05-31",{"name":168,"class":53},"Centre Hospitalier Intercommunal Creteil",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":21,"phases":179,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":54},"100514514","phase-4-ql-block-in-laparoscopic-myomectomy-100514514","NCT05979493","QL Block in Laparoscopic Myomectomy","Quadratus Lumborum Block to Improve Postoperative Pain Management After Laparoscopic Myomectomies: a Double-blinded and Prospective Randomized Clinical Trial.","Inclusion Criteria:\n\n* Presence of uterine fibroids requiring surgical excision with preservation of the uterus\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Provision of signed and dated informed consent form\n\nExclusion Criteria:\n\n* Pre-existing diagnoses of anxiety or depression\n* Pre-existing coagulopathies\n* Pre-existing neuropathic or chronic pelvic pain\n* Chronic opioid use\n* Illiteracy due to inability to read and understand plain questionnaire\n* Non-English speaking\n* BMI \\>38","45 Years",{"count":178,"type":20},80,[23],"This study aims to determine the efficacy of a quadratus lumborum (QL) block in decreasing postoperative pain in patients undergoing myomectomy for uterine fibroids. A QL block is a temporary anesthetic injection in the quadratus lumborum muscle, a muscle in the lower back, that has been previously shown to significantly reduce postoperative pain levels in patients undergoing abdominal and pelvic surgery. Because of its demonstrated effects, the QL block is becoming a standard of anesthesia and surgical care. Since participants will be undergoing a myomectomy procedure, the investigators believe that participants may qualify to participate in this study. The investigators will be comparing patients who receive the QL block (in addition to standard anesthesia and postoperative pain care) with patients who do not receive the QL block (in addition to standard care). The participants will be randomly assigned to one of the two groups and may or may not actually receive the block.",[182,29],"Postoperative Pain",[184,185],"QL Block","Myomectomy","2025-08-05",{"date":188,"type":46},"2025-08-06",{"date":190,"type":46},"2024-08-24",{"date":192,"type":20},"2026-07-03",{"name":194,"class":53},"Joseph Findley MD",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":202,"enrollmentInfo":203,"targetDuration":4,"studyType":21,"phases":205,"briefSummary":206,"conditions":207,"keywords":210,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":54},"100316534","phase-2-effects-of-simvastatin-on-uterine-leiomyoma-size-100316534","NCT03400826","Effects of Simvastatin on Uterine Leiomyoma Size","A Double-blinded, Phase II, Randomized Control Trial to Study the Effects of Simvastatin in Patients With Uterine Leiomyoma","Inclusion Criteria:\n\n* Signed informed written consent.\n* Gender: female.\n* Age: 18-55 years at time of signing consent.\n* BMI of subjects: \\\u003C 45 kg\u002Fm2.\n* Uterine fibroids:\n* Diagnosed by ultrasound (MRI will be used only if ultrasound is inconclusive).\n* Number: any number of fibroids.\n* Location: submucosal or intramural.\n* At least one fibroid of diameter \\> 3cm.\n* Symptoms: one or more of the following symptoms of heavy menstrual bleeding (HMB), defined as: Experienced cyclic (22 to 35 days) abnormal uterine bleeding (heavy or prolonged) in at least 3 of the last 6 menstrual periods, including menstrual bleeding lasting 5 or more days or heavy bleeding per participant recall. Examples of heavy bleeding may include, but are not limited to the following:\n* Requires the use of double protection to manage menstrual bleeding.\n* Menstrual bleeding accompanied by the sensation of \"gushing\" or \"flooding\".\n* Saturates more than 1 tampon or sanitary pad per hour for 3 or more consecutive hours.\n* Regularly needs to change the tampon or sanitary pad at night or regularly soils bedclothes.\n* Heavy bleeding that affects work, school, or social activities.\n* Pelvic pain\u002F pressure likely caused by fibroids.\n* Plan for surgery (hysterectomy or myomectomy).\n* Normal Pap smear within the last year.\n* Use of contraception during study such as non-hormonal oral contraceptives, intrauterine devices (IUD)\u002F intrauterine systems (IUS), barrier contraceptives, abstinence or sterilization.\n\nExclusion Criteria:\n\n* Pregnancy or lactation.\n* Previous or current uterine, cervical or ovarian cancer.\n* Current endometrial hyperplasia or history of atypical endometrial hyperplasia. Endometrial biopsy will be done during screening (if not done within last 12 months).\n* Suspicion of leiomyosarcoma.\n* Recent rapid growth of fibroids (i.e. doubling in size within 1-6 months period).\n* Unevaluated gynecologic abnormalities (unexplained vaginal bleeding, cervical dysplasia, or abnormal adnexal\u002Fovarian mass).\n* Menopausal status.\n* Surgery is urgently indicated (\\\u003C 3 months) for medical or social reasons.\n* Hemoglobin ≤ 6 g\u002FdL.\n* Currently enrolled in another investigational study.\n* Mental condition or other barrier preventing informed written consent.\n* Allergy or hypersensitivity to simvastatin.\n* Current use of simvastatin or other drugs of the same class.\n* Concomitant administration of strong CYP3A4 inhibitors including itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, and cobicistat-containing products.\n* Concomitant administration of gemfibrozil, cyclosporine, or danazol, verapamil, diltiazem, amiodarone, diltiazem, dronedarone, amlodipine, ranolazine, lomitapide, and grapefruit juice.\n* Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels.( elevation of aspartate transaminase and\u002For alanine transaminase \\> 2 s.d. above the normal range at screening visit)\n* Known increased risk or diagnosis of a myopathy.","55 Years",{"count":204,"type":20},60,[95],"The study aims to study the effect of simvastatin on the size of uterine fibroids.",[29,208,72,209,71],"Fibroid Tumor","Fibromyoma",[211,212,213,214,215],"simvastatin","fibroids","medical management","uterine fibroids","leiomyoma","2025-07-09",{"date":218,"type":46},"2025-07-14",{"date":220,"type":46},"2018-08-20",{"date":222,"type":20},"2026-07-31",{"name":109,"class":53},{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":63,"sex":16,"minAge":17,"maxAge":176,"enrollmentInfo":232,"targetDuration":4,"studyType":148,"phases":4,"briefSummary":234,"conditions":235,"keywords":236,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":54},"100592297","fertility-limiting-diseases-of-pelvic-organs-and-their-influence-on-receptivity-of-endometrial-cavity-prospective-clinical-trial-100592297","NCT06991595","Fertility Limiting Diseases of Pelvic Organs and Their Influence on Receptivity of Endometrial Cavity: Prospective Clinical Trial","Fertility Limiting Diseases of Pelvic Organs and Their Influence on Receptivity of Endometrial Cavity: Prospective Clinical Trial (REAdME)","REAdME","Inclusion Criteria:\n\n* agreement with participation in the study\n* age between 18 - 45 years (at the start of patient´s participation in the study)women with at least 1 year infertility\n\nExclusion Criteria:\n\n\\-",{"count":233,"type":20},236,"In this project, we will characterize the effects of fertility limiting diseases of pelvic organs on the receptivity of the endometrium. The primary aim of the project is the characterization of endometrium in patients with infertility suffering from AD, UF and DE, and compare it with infertile patients with minimal or mild endometriosis but no AD or UF (ETRS group), and with healthy women with only male factor of infertility (CTRL group, controls). The proper infertility treatment of patients with AD,UF and endometriosis is controversial and lacking clear evidence based algorithms. Despite their topical character, especially AD and DE (and UFs as well if present as multiple lesions) can be classified as systemic diseases in relation to women´s fertility. The presumed impact of these pathologies to endometrial receptivity (no matter they do not occur in the uterine cavity itself) can beseen as a fascinating hypothesis. Eradication of these diseases could have a potential to increase the prognosis of these women fundamentally.",[127,29,31],[237,238,239,240,241],"adenomyosis","cytoreductive resection","myomectomy","endometriosis","endometrial receptivity","2025-05-18",{"date":244,"type":46},"2025-05-28",{"date":246,"type":46},"2023-04-01",{"date":248,"type":20},"2026-12-31",{"name":250,"class":53},"Charles University, Czech Republic",{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":21,"phases":260,"briefSummary":261,"conditions":262,"keywords":263,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":278},"100536821","temporary-artery-clipping-for-robotically-assisted-myomectomy-a-multicentric-randomized-controlled-trial-100536821","NCT06269809","Temporary Artery Clipping for Robotically-assisted Myomectomy, a Multicentric Randomized Controlled Trial","TACROM","Inclusion Criteria:\n\nParticipants eligible for inclusion in this Trial must meet all of the following criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n2. Use of highly effective methods of birth control; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatment(s)) or commitment to a vasectomised partner.\n3. Female\n4. Age: 18-50 years\n5. Myomas, eligible for myomectomy, with the exclusion of FIGO 7-8 myomas.\n\nExclusion Criteria:\n\nParticipants eligible for this Trial must not meet any of the following criteria:\n\n1. Any disorder, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol\n2. Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Trial\n3. Participation in an interventional Trial with an investigational medicinal product (IMP) or device\n4. Patient refusal to participate in the Trial\n5. (Possible) malignancy\n6. any contra indication for a laparoscopic or robotic surgery",{"count":259,"type":20},82,[123],"This study aims to investigate the efficacy of temporary clipping of the uterine artery and utero-ovarian ligament during robotically assisted myomectomy (RAM) for uterine fibroids. While RAM is increasingly used for myomectomy, bleeding control remains challenging. Temporary clipping of arteries has shown promise in conventional laparoscopy but has not been studied in RAM. This randomized controlled trial will assess primary endpoints such as estimated blood loss, need for transfusion, and hemoglobin drop, alongside secondary outcomes like complication rates and operation time.",[29],[239,264,265,266,267,268],"fibroid","myoma","blood loss","temporary artery clipping","hemostatic measures","2025-03-11",{"date":271,"type":46},"2025-03-14",{"date":273,"type":46},"2023-05-04",{"date":275,"type":20},"2025-05-30",{"name":277,"class":53},"Universitaire Ziekenhuizen KU Leuven",4]